Cancer Genetics to Buy vivoPharm for $12M
Cancer Genetics (CGI) is buying cancer drug discovery and preclinical services company vivoPharm, for $12 million in cash and shares. CGI said it expects the acquisition to strengthen its position as a provider of services for oncology discovery, in vivo and in vitro drug development, and early-phase clinical trials testing, and expand its presence in Europe and Australia. The acquisition, which has been approved by both companies’ boards, is projected to close today.